A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Launched by FONDAZIONE ITALIANA LINFOMI - ETS · Feb 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment option for older patients with a type of cancer called diffuse large B-cell non-Hodgkin lymphoma (DLBCL). The researchers want to see how effective a combination of two drugs, rituximab and CC-99282, is when used together without traditional chemotherapy. This trial is specifically aimed at older patients who are considered frail and are not suitable for standard treatments due to their health conditions.

To be eligible for this trial, participants must be at least 80 years old, have a confirmed diagnosis of DLBCL, and have never received treatment for this cancer before. They also need to have certain health requirements, such as being able to manage basic daily activities and having measurable disease that can be tracked during the study. Participants can expect to take the study drugs and attend regular appointments for monitoring their health. This trial is not yet recruiting, but it represents an important step in exploring gentler treatment options for older adults with cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Able to provide written informed consent form approved by the National Ethics Committee (NEC) prior to the initiation of any screening or study- specific procedures and able to understand and to comply with the requirements of the study and the schedule of assessments.
• • 2. Histologically documented diagnosis of DLBCL as defined in the 5th edition of the World Health Organization (WHO) classification (2022)
• • 3. Previously untreated
• • 4. Frail patients defined as follows (Appendix A-D): Age ≥ 80 years: activity of daily living (ADL) \< 6 residual functions and/or Instrumental activity of daily living (IADL) \< 8 residual functions and/or cumulative illness rating scale (CIRS) \> 5 comorbidities of grade 2 and/or one or more comorbidities of grade 3-4
• • 5. Patient not eligible to anthracycline-based chemotherapy
• • 6. Ann Arbor Stage I - IV (Appendix E)
• • 7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3 (Appendix F)
• • 8. At least one site of measurable nodal disease at baseline \[≥ 1.5 cm\] in the longest transverse diameter as determined by CT scan
• 9. Adequate hematological counts defined as follows:
• • WBC \> 2.5 x 109/L with ANC \> 1.0 x 109/L unless due to bone marrow involvement by lymphoma
• • Platelet count ≥ 75 x 109/L unless due to bone marrow involvement by lymphoma
• • Hemoglobin ≥ 10 g/dL unless anemia related to active lymphoma
• • 10. Adequate renal function defined as creatinine clearance ≥ 30 mL/min (Appendix G). The same CrCl cutoff applies in case of documented renal involvement by lymphoma
• 11. Adequate hepatic function per local laboratory reference range, unless secondary to lymphoma, as follows:
• • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.0 x ULN
• • Bilirubin ≤ 2 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin, i.e. mild and chronic hemolysis)
• • 12. Subject must be able to adhere to the study visit schedule and other protocol requirements
• • 13. Subject must be able to swallow capsules or tablets
• • 14. Life expectancy ≥ 3 months
• • 15. Male subjects must practice complete abstinence when this is in line with the usual lifestyle (periodic abstinence is not permitted) or agree to use specified contraceptive methods (barrier contraception: condom) during sexual contact with a female of childbearing potential while participating in the study, for at least 28 days following investigational product discontinuation, even if he has undergone a successful vasectomy. Furthermore, they do not have to donate sperm during the study and for at least 28 days after receiving the last dose of study drug. If applicable, male subjects must receive study specific Pregnancy Prevention Plan (PPP).
• Exclusion Criteria:
• • 1. Histological diagnosis different from DLBCL
• • 2. Central nervous system (CNS) involvement with lymphoma
• • 3. Severe heart failure (NYHA grado III-IV and/or LVEF \< 45%), liver disease Child Pugh C, history of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis, or pulse oximetry of \< 92% while breathing room air, or any other clinical condition that would preclude participation in the study or compromise ability to give informed consent
• • 4. Any history of other active malignancies within 5 years prior to study entry, except for adequately treated in situ carcinoma of the cervix uterine, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin, previous malignancy confined and surgically resected with curative intent
• • 5. Gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy) or any other malabsorption condition
• 6. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
• • 1. Uncontrolled and/or active systemic infection (viral, bacterial or fungal), including active ongoing infection from SARS-CoV-2
• • 2. Chronic or acute hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV i.e. hepatitis B surface (HBs) antigen (Ag) negative, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative, may participate; patients with positive anti-HBc antibody from previous infection or inactive carriers are eligible only with HBV-DNA negative and with concomitant treatment with Lamivudine or Tenofovir
• • 3. Patients with presence of HCV antibody are eligible only if PCR negative for HCV-RNA
• • 7. Human immunodeficiency virus (HIV) seropositivity
• • 8. Absence of caregivers in non-autonomous patients
• • 9. Allergy or intolerance to the active or inactive ingredients of study drugs